Clendeninn NJ - Search Results

1

Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days.

Bailey H, Kohler P, Tuttle R, Carbone PP, Hohneker JA, Clendeninn NJ, Wilding G. Bailey H, et al. Among authors: clendeninn nj. Invest New Drugs. 1992 Nov;10(4):279-87. doi: 10.1007/BF00944182. Invest New Drugs. 1992. PMID: 1487401 Clinical Trial.

2

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.

Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G. Berlin J, et al. Among authors: clendeninn nj. Invest New Drugs. 1994;12(2):137-41. doi: 10.1007/BF00874444. Invest New Drugs. 1994. PMID: 7860231 Clinical Trial.

3

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder.

Khorsand M, Lange J, Feun L, Clendeninn NJ, Collier M, Wilding G. Khorsand M, et al. Among authors: clendeninn nj. Invest New Drugs. 1997;15(2):157-63. doi: 10.1023/a:1005860806635. Invest New Drugs. 1997. PMID: 9220296 Clinical Trial.

4

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.

Schilsky RL, Ratain MJ, Janisch L, Vogelzang NJ, Lucas VS, Ravitch J, Hohneker JA, Clendeninn NJ, Tuttle RL. Schilsky RL, et al. Among authors: clendeninn nj. Cancer Chemother Pharmacol. 1993;31(4):283-8. doi: 10.1007/BF00685672. Cancer Chemother Pharmacol. 1993. PMID: 8422691 Clinical Trial.

5

Oral piritrexim--a phase II study in patients with advanced soft tissue sarcoma.

Schiesel JD, Carabasi M, Magill G, Casper E, Cheng E, Marks L, Feyzi J, Clendeninn NJ, Smalley RV. Schiesel JD, et al. Among authors: clendeninn nj. Invest New Drugs. 1992 Jul;10(2):97-8. doi: 10.1007/BF00873124. Invest New Drugs. 1992. PMID: 1500271 Clinical Trial. No abstract available.

6

Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.

Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. Jhawer M, et al. Invest New Drugs. 2007 Feb;25(1):85-94. doi: 10.1007/s10637-006-9003-x. Epub 2006 Sep 7. Invest New Drugs. 2007. PMID: 16957834 Clinical Trial.

7

Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor.

Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G. Hande KR, et al. Clin Cancer Res. 2004 Feb 1;10(3):909-15. doi: 10.1158/1078-0432.ccr-0981-3. Clin Cancer Res. 2004. PMID: 14871966 Clinical Trial.

8

Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies.

Feun LG, Savaraj N, Benedetto P, Hanlon J, Sridhar KS, Collier M, Richman S, Liao SH, Clendeninn NJ. Feun LG, et al. Among authors: clendeninn nj. J Natl Cancer Inst. 1991 Jan 2;83(1):51-5. doi: 10.1093/jnci/83.1.51. J Natl Cancer Inst. 1991. PMID: 1984518 Clinical Trial.

9

Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.

Adamson PC, Balis FM, Miser J, Wells RJ, Bleyer WA, Williams TE, Gillespie A, Penta JS, Clendeninn NJ, Poplack DG. Adamson PC, et al. Among authors: clendeninn nj. Cancer Res. 1990 Aug 1;50(15):4464-7. Cancer Res. 1990. PMID: 2369724

10

Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.

Adamson PC, Balis FM, Miser J, Arndt C, Wells RJ, Gillespie A, Aronson L, Penta JS, Clendeninn NJ, Poplack DG. Adamson PC, et al. Among authors: clendeninn nj. Cancer Res. 1992 Feb 1;52(3):521-4. Cancer Res. 1992. PMID: 1732038 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters